Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
Sell
34
BIO Quote, Financials, Valuation and Earnings
Last price:
$253.59
Seasonality move
:
5.68%
Day range:
$240.22 - $245.87
52-week range:
$215.38 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.69x
P/B ratio:
1.04x
Volume:
214.9K
Avg. volume:
414.6K
1-year change:
-12.55%
Market cap:
$6.9B
Revenue:
$2.6B
EPS (TTM):
-$65.04
Analysts' Opinion
-
Consensus RatingBio-Rad Laboratories has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $353.17, Bio-Rad Laboratories has an estimated upside of 44.16% from its current price of $244.98.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $270.00 representing 100% downside risk from its current price of $244.98.
Fair Value
-
According to the consensus of 5 analysts, Bio-Rad Laboratories has 44.16% upside to fair value with a price target of $353.17 per share.
BIO vs. S&P 500
-
Over the past 5 trading days, Bio-Rad Laboratories has underperformed the S&P 500 by -1.95% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Rad Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Rad Laboratories revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Rad Laboratories reported revenues of $667.5M.
Earnings Growth
-
Bio-Rad Laboratories has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Bio-Rad Laboratories reported earnings per share of -$25.57.
Enterprise value:
6.4B
EV / Invested capital:
--
Price / LTM sales:
2.69x
EV / EBIT:
--
EV / Revenue:
2.49x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
24.04x
Price / Operating cash flow:
25.98x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.4B
Return On Assets:
-16.9%
Net Income Margin (TTM):
-71.86%
Return On Equity:
-23.87%
Return On Invested Capital:
-20.67%
Operating Margin:
8.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $2.8B | $2.7B | $2.6B | $681.1M | $667.5M | |
| Gross Profit | $1.6B | $1.4B | $1.4B | $366.3M | $341.9M | |
| Operating Income | $475.1M | $337.8M | $269M | $95.3M | $58.3M | |
| EBITDA | -$4.5B | -$654.8M | -$2.1B | $477.9M | -$857.5M | |
| Diluted EPS | -$121.25 | -$21.49 | -$65.04 | $12.14 | -$25.57 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.1B | $2B | $3.2B | $3B | $3B | |
| Total Assets | $13B | $17.8B | $13.5B | $12.3B | $9.4B | |
| Current Liabilities | $631.5M | $680.9M | $568.7M | $522.8M | $467.8M | |
| Total Liabilities | $3.1B | $4.1B | $3.9B | $3.6B | $2.8B | |
| Total Equity | $9.9B | $13.7B | $9.6B | $8.7B | $6.6B | |
| Total Debt | $2.6M | $11M | $1.2B | $1.2B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $194.4M | $374.9M | $455.2M | $81M | $124.2M | |
| Cash From Investing | -$1.2B | $20.2M | -$160.2M | $72.2M | -$30.5M | |
| Cash From Financing | $973.6M | -$425.6M | -$218.8M | -$200.6M | -$26.2M | |
| Free Cash Flow | $80.1M | $218.2M | $266.2M | $38.7M | $81.2M | |
BIO
Sector
Market Cap
$6.9B
$34.9M
Price % of 52-Week High
63.14%
42.85%
Dividend Yield
0%
0%
Shareholder Yield
2.19%
-0.82%
1-Year Price Total Return
-12.55%
-40.42%
Beta (5-Year)
1.119
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$242.24
200-day SMA
Sell
Level
$314.06
Bollinger Bands (100)
Sell
Level
256.23 - 345.99
Chaikin Money Flow
Buy
Level
25.5M
20-day SMA
Buy
Level
$240.46
Relative Strength Index (RSI14)
Sell
Level
48.67
ADX Line
Sell
Level
31.1
Williams %R
Neutral
Level
-20.0648
50-day SMA
Sell
Level
$261.57
MACD (12, 26)
Sell
Level
-5.64
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
21.9M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8785)
Sell
CA Score
(Annual)
Level (-0.378)
Buy
Beneish M-Score
(Annual)
Level (-3.6873)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.345)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Stock Forecast FAQ
In the current month, BIO has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BIO average analyst price target in the past 3 months is $353.17.
-
Where Will Bio-Rad Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Rad Laboratories share price will rise to $353.17 per share over the next 12 months.
-
What Do Analysts Say About Bio-Rad Laboratories?
Analysts are divided on their view about Bio-Rad Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Rad Laboratories is a Sell and believe this share price will drop from its current level to $270.00.
-
What Is Bio-Rad Laboratories's Price Target?
The price target for Bio-Rad Laboratories over the next 1-year time period is forecast to be $353.17 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Rad Laboratories is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BIO?
You can purchase shares of Bio-Rad Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Rad Laboratories shares.
-
What Is The Bio-Rad Laboratories Share Price Today?
Bio-Rad Laboratories was last trading at $253.59 per share. This represents the most recent stock quote for Bio-Rad Laboratories. Yesterday, Bio-Rad Laboratories closed at $244.98 per share.
-
How To Buy Bio-Rad Laboratories Stock Online?
In order to purchase Bio-Rad Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Is TSMC the Best Semiconductor Stock to Buy Now?
The new administration has launched a slew of tariffs, paused…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 34x
Alerts
Buy
56
ROOT alert for Apr 23
Root [ROOT] is up 10.13% over the past day.
Buy
72
EFX alert for Apr 23
Equifax [EFX] is up 1.56% over the past day.
Buy
51
CALX alert for Apr 23
Calix [CALX] is down 0.8% over the past day.
